Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson (NYSE: JNJ) generates a steady flow of news across Innovative Medicine and MedTech, reflecting its role in pharmaceutical preparation manufacturing and medical technologies. On this news page, readers can follow company announcements on clinical trial results, regulatory milestones, strategic transactions, manufacturing investments and corporate actions.
Recent oncology news includes positive topline data from the Phase 3 MajesTEC-9 study of TECVAYLI (teclistamab-cqyv) monotherapy in relapsed or refractory multiple myeloma, where Johnson & Johnson reported a substantial reduction in the risk of disease progression or death versus standard of care in a population predominantly refractory to anti-CD38 therapy and lenalidomide. The company has also shared longer-term results from the OrigAMI-1 study of RYBREVANT (amivantamab-vmjw) plus chemotherapy in metastatic colorectal cancer, supporting further Phase 3 evaluation of amivantamab-based regimens in first- and second-line settings.
In neuroscience and mental health, Johnson & Johnson has highlighted new data on CAPLYTA (lumateperone), SPRAVATO (esketamine) and the investigational agent seltorexant at major scientific meetings, including analyses focused on remission in major depressive disorder, treatment-resistant depression and sleep-related symptoms. The company has also announced positive Phase 2b results for nipocalimab in systemic lupus erythematosus and plans to initiate a Phase 3 program, underscoring its activity in autoantibody-driven diseases.
MedTech news covers developments such as the FDA submission of the OTTAVA robotic surgical system for De Novo classification, supported by an IDE study in gastric bypass procedures, and an expanded indication for the TRUFILL n‑BCA Liquid Embolic System for chronic subdural hematoma. Corporate and financial updates, including quarterly dividend declarations, U.S. manufacturing investments and government agreements to improve access to medicines, also appear in Johnson & Johnson’s news flow. Investors, clinicians and observers can use this page to monitor how Johnson & Johnson’s clinical, regulatory and strategic decisions evolve over time.
Johnson & Johnson (NYSE: JNJ) announced FDA approval of a new monthly dosing schedule for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combined with oral LAZCLUZE for first-line EGFR-mutated advanced NSCLC, available as early as Week 5.
The approval preserves established efficacy and safety versus the bi-weekly subcutaneous schedule, shows pharmacokinetic comparability to prior IV and SC regimens, and reports a fivefold reduction in administration-related reactions versus historical IV delivery.
Summary not available.
Johnson & Johnson (NYSE: JNJ) will present at the Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026, with management in a Fireside Chat at 11:30 a.m. ET. A live audio webcast and an archived replay (available ~48 hours later) will be on the company's investor website.
Johnson & Johnson (NYSE: JNJ) presented 12-month pilot-phase OMNY-AF results showing 90% freedom from atrial fibrillation and 100% acute procedural success across a 30-patient cohort, with no procedure-related adverse events and 56.7% of cases using zero fluoroscopy.
Presentations also highlighted VARIPULSE platform safety: a 0.22% neurovascular event rate in 6,811 patients after workflow and irrigation optimizations, and high same-day discharge rates.
Johnson & Johnson (NYSE: JNJ) will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026.
Management will take part in a Fireside Chat at 11:10 a.m. ET. A live audio webcast will be available on the company’s Investor Relations website, with an archived replay posted approximately 48 hours after the event.
Johnson & Johnson (NYSE:JNJ) announced FDA approval (Jan 27, 2026) of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) combined with bortezomib, lenalidomide and dexamethasone (D-VRd) for adult newly diagnosed multiple myeloma patients who are transplant ineligible.
CEPHEUS Phase 3 results: overall MRD-negativity 52.3% vs 34.8% (sensitivity 10-5) at 22 months; sustained MRD≥12 months 42.6% vs 25.3% at 39 months; progression or death reduced 40% (HR 0.60; 95% CI 0.41–0.88). At ~59 months, complete response or better was 81.2% vs 61.6%. Overall survival data not yet mature.
Johnson & Johnson (NYSE: JNJ) announced it has donated $100 million of MedTech products since 2020 and plans an additional $20 million in 2026 to support programs and impact investments that expand access to cardiovascular, surgical and vision care. These commitments operate under J&J CareCommunity and involve partners including Lions Clubs International Foundation, Operation Smile, American Heart Association and Global Surgery Foundation. The effort reaches over 300,000 healthcare professionals annually and includes a $1 million commitment to SURGfund and long‑running programs such as Sight For Kids, which has reached > 55 million students.
Johnson & Johnson (NYSE: JNJ) reported Q4 2025 sales of $24.6B (+9.1% reported; operational +7.1%) and full‑year 2025 sales of $94.2B (+6.0% reported; operational +5.3%).
Q4 diluted EPS was $2.10 and full‑year diluted EPS was $11.03; adjusted diluted EPS was $2.46 for Q4 and $10.79 for full year. Results include a $(0.10) EPS impact from the acquisition of Halda Therapeutics. Free cash flow for 2025 is ~$19.7B.
Notable developments: FDA approvals (including CAPLYTA and RYBREVANT FASPRO plus LAZCLUZE), landmark TECVAYLI plus DARZALEX FASPRO data, completion of the Halda acquisition, and submission of the OTTAVA robotic surgical system. 2026 guidance midpoint: estimated reported sales $100.5B (+6.7%) and adjusted EPS $11.53 (+6.9%).
Johnson & Johnson (NYSE:JNJ) reported positive topline Phase 3 MajesTEC-9 results for TECVAYLI monotherapy in relapsed/refractory multiple myeloma. TECVAYLI reduced the risk of disease progression or death by 71% (HR=0.29, 95% CI: 0.23–0.38) and the risk of death by 40% (HR=0.60, 95% CI: 0.43–0.83) versus standard of care. The trial enrolled patients with 1–3 prior therapies; most were refractory to anti‑CD38 (85%) and lenalidomide (79%). Safety was described as clinically manageable with no new safety concerns; the IDMC recommended unblinding after a pre‑specified interim analysis. Full results will be presented at a future medical meeting.
Johnson & Johnson (NYSE: JNJ) will present 11 abstracts at the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Jan 12–15, 2026, in Nassau, Bahamas. Presentations cover Phase 3 and preclinical neuropsychiatry research across major depressive disorder (MDD), treatment-resistant depression (TRD), schizophrenia, and discovery work.
Key items include Phase 3 analyses of lumateperone (CAPLYTA) for remission in adjunctive MDD, metabolic and tolerability data comparing adjunctive seltorexant vs quetiapine XR in MDD with insomnia, and post-hoc Phase 3 analyses of esketamine (SPRAVATO) on anhedonia in TRD, plus AI and biomarker discovery posters.